Company Description
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS).
Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death.
The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017.
Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
| Country | United States |
| Founded | 1971 |
| IPO Date | Jul 19, 1990 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 210 |
| CEO | Mitchell Steiner |
Contact Details
Address: 2916 North Miami Avenue, Suite 1000 Miami, Florida 33127 United States | |
| Phone | 305 509 6897 |
| Website | verupharma.com |
Stock Details
| Ticker Symbol | VERU |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0000863894 |
| CUSIP Number | 92536C103 |
| ISIN Number | US92536C1036 |
| Employer ID | 39-1144397 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mitchell S. Steiner F.A.C.S., M.D. | Chairman, President and Chief Executive Officer |
| Dr. Harry D. Fisch F.A.C.S., M.D. | Vice Chairman and Chief Corporate Officer |
| Dr. K. Gary Barnette Ph.D. | Chief Scientific Officer |
| Michele Greco CPA | Chief Financial Officer and Chief Administrative Officer |
| Samuel Fisch | Executive Director of Investor Relations and Corporate Communications |
| Michael J. Purvis J.D. | Executive Vice President, General Counsel and Corporate Strategy and Secretary |
| Kevin J. Gilbert CPA, J.D. | Executive Vice President of Corporate Development |
| Martin Tayler | Executive Vice President of FC2 Global Operations |
| Philip R. Greenberg J.D. | Executive Vice President and Deputy General Counsel |
| Dr. Domingo Rodriguez M.D. | Executive Vice President of Global Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 14, 2025 | 8-K | Current Report |
| Feb 28, 2025 | 8-K | Current Report |
| Feb 13, 2025 | 10-Q | Quarterly Report |
| Feb 13, 2025 | 8-K | Current Report |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Jan 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 28, 2025 | DEF 14A | Other definitive proxy statements |
| Jan 3, 2025 | 8-K | Current Report |
| Dec 16, 2024 | EFFECT | Notice of Effectiveness |
| Dec 16, 2024 | 10-K | Annual Report |